These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30468868)

  • 1. Model-informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population.
    Vozmediano V; Lukas JC; Encinas E; Schmidt S; Sologuren A; Valiente R; Labeaga L; Campo C; Rodriguez M
    Eur J Pharm Sci; 2019 Feb; 128():180-192. PubMed ID: 30468868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
    Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
    Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.
    Vozmediano V; Sologuren A; Lukas JC; Leal N; Rodriguez M
    Pharm Res; 2017 Dec; 34(12):2720-2734. PubMed ID: 28971281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of bilastine: 2nd generation H1-antihistamines.
    Scaglione F
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
    Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
    Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How bilastine is used to treat allergic rhinitis and urticaria in children.
    Rodríguez Del Río P; Rodríguez Fernández F; Ballester Asensio E; Tortajada-Girbés M
    Immunotherapy; 2022 Jan; 14(1):77-89. PubMed ID: 34850647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
    Togawa M; Yamaya H; Rodríguez M; Nagashima H
    Clin Drug Investig; 2016 Dec; 36(12):1011-1021. PubMed ID: 27498100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M; Yagami A; Togawa M; Saito A; Furue M
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
    Yagami A; Furue M; Togawa M; Saito A; Hide M
    J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
    Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
    Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilastine for the relief of allergy symptoms.
    Sádaba Díaz de Rada B; Azanza Perea JR; Gomez-Guiu Hormigos A
    Drugs Today (Barc); 2011 Apr; 47(4):251-62. PubMed ID: 21573249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
    Wolthers OD
    Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study.
    Sádaba B; Azanza JR; García-Bea A; Labeaga L; Campo C; Valiente R
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):265-272. PubMed ID: 31820304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilastine: in allergic rhinitis and urticaria.
    Carter NJ
    Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral availability of bilastine.
    Sádaba B; Gómez-Guiu A; Azanza JR; Ortega I; Valiente R
    Clin Drug Investig; 2013 May; 33(5):375-81. PubMed ID: 23529786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
    Demonte A; Guanti MB; Liberati S; Biffi A; Fernando F; Fainello M; Pepe P
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):820-828. PubMed ID: 29461615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial.
    Okubo K; Gotoh M; Togawa M; Saito A; Ohashi Y
    Auris Nasus Larynx; 2017 Jun; 44(3):294-301. PubMed ID: 27561709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
    Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
    Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
    Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
    Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.